Watch this OncLive interview with University of Illinois Cancer Center Deputy Director VK Gadi, MD, PhD, about AMUN-003 in triple-negative breast cancer, a newly developed oncolytic adenovirus that expresses both soluble transforming growth factor receptor II and granulocyte-macrophage colony-stimulating factor. Its efficacy as a single agent and in combination with immunotherapy was evaluated in preclinical models and presented at the San Antonio Breast Cancer Symposium in December.